Spyre Therapeutics, Inc.
SYRE
Classificação em ações
#2338
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical... Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
Preço da ação
$91.87
Última sincronização: 2026-10-20
Valor de mercado
$8.48B
Variação (1 dia)
8.44%
Variação (1 ano)
295.14%
País
US
Negociar Spyre Therapeutics, Inc. (SYRE)
Categoria
Healthcare
Lucros da Spyre Therapeutics, Inc. (SYRE)
Lucros em Jun 2026 TTM: $-178.92M
De acordo com os últimos relatórios financeiros da Spyre Therapeutics, Inc., os ganhos atuais da empresa são de $-178.92M. Em 2023, a empresa teve ganhos de $-338.82M, uma diminuição em relação a aos ganhos de 2022, que foram de $-83.95M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Spyre Therapeutics, Inc. de 2014 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $-178.92M | -13.97% |
| 2024 | $-207.97M | -38.62% |
| 2023 | $-338.82M | 303.59% |
| 2022 | $-83.95M | 27.86% |
| 2021 | $-65.66M | -18.83% |
| 2020 | $-80.89M | 3.37% |
| 2019 | $-78.25M | 76.45% |
| 2018 | $-44.35M | 62.83% |
| 2017 | $-27.24M | 25.52% |
| 2016 | $-21.70M | 92.10% |
| 2015 | $-11.30M | 9.16% |
| 2014 | $-10.35M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $5.27B | -3,048.22% |
US
|
|
| $-3.09B | 1,625.37% |
US
|
|
| $-4.02B | 2,144.71% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,190.25% |
NL
|
